Asparlas is a pharmaceutical agent that treats the cute lymphoblastic leukemia in pediatric and young adult patients aged one month to 21 years.
The drug is an asparagine specific enzyme that’s is meant to be used as a component of a multi-agent chemotherapeutic regimen for acute lymphoblastic leukemia.
Common side effects include elevated transaminase, bilirubin increased, pancreatitis, abnormal clotting studies, diarrhea, hypersensitivity, shortness of breast, bleeding, pneumonia and abnormal heart rate.
Filed Under: Drug Discovery, Drug Discovery and Development, Neurological Disease, Oncology, Orphan Drugs
Tell Us What You Think!
You must be logged in to post a comment.